Amgen has kicked back at Sanofi and Regeneron’s attempt to keep their cholesterol drug Praluent on the market while an appeals court sorts out a patent dispute.

Sanofi, Novo Nordisk and Eli Lilly face a class action lawsuit claiming that an insulin pricing "arms race" left patients with staggering expenses.

The EpiPen saga isn’t over. The FTC is investigating Mylan's efforts to stave off generic versions of its blockbuster device.

It’s deja vu for Teva in a bad, bad way. A U.S. court struck down four patents on its long-acting version of multiple sclerosis star Copaxone, putting billions…

Teva is eager to start moving in the right direction after a particularly rocky 2016. Problem is, it’s still paying for pay-for-delay decisions made by its…

As Sanofi and Regeneron scramble to keep their cholesterol drug Praluent on the market amid a contentious patent fight, Amgen’s rival drug Repatha already…

Novartis' legal fight with Amgen over its biosimilar of Enbrel will not be resolved before next year.

A top U.S. health official says there’s no settlement with Mylan, adding yet another twist to the company’s prolonged EpiPen episode.

Sanofi and Regeneron asked a U.S. appeals court to let them continue selling their PCSK9 drug Praluent while a bitter patent dispute with Amgen continues.…

Legal